Therapeutics

The conclusion that there was nothing wrong with the specifics of the TeGenero trial in which six healthy volunteers ended up in intensive care has repercussions for the wider biotech industry.

After finding nothing wrong with the specifics of the preclinical data, the product, or how the trial was conducted, the UK Medicines and Healthcare Products Regulatory Agency has ordered an investigation to changes in clinical trials procedures.